Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.38 |
| ▸ | HTR2C | P28335 | 6/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29688814 | 1.00 | CHRM4 (0.39) | CHRM4TLR9TLR8TLR7HTR2C | |
| SCHEMBL20135195 | 0.85 | SLC6A2 (0.38) | CHRM4TLR9TLR8TLR7HTR2C | |
| SCHEMBL24161237 | 0.73 | TLR9 (0.56) | TLR9TLR8TLR7 | |
| Acetic Acid SCHEMBL7965027 | 0.72 | HTR2C (0.41) | TLR9TLR8TLR7HTR2CGABRA1 | |
| SCHEMBL20809378 | 0.71 | CHRM4 (0.38) | CHRM4TLR9TLR8TLR7HTR2C | |
| Hydrochloric Acid SCHEMBL20134911 | 0.70 | HTR2C (0.37) | CHRM4TLR9TLR8TLR7HTR2C | |
| Hydrochloric Acid SCHEMBL29688639 | 0.70 | HTR2C (0.37) | CHRM4TLR9TLR8TLR7HTR2C | |
| SCHEMBL20135330 | 0.69 | HTR2C (0.42) | CHRM4TLR9TLR8TLR7HTR2C | |
| SCHEMBL20809374 | 0.69 | GRIN2D (0.39) | ITK | |
| SCHEMBL5546531 | 0.69 | HTR2C (0.48) | HTR2CMEN1KMT2AGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922347-B | Novel imide derivatives and their use as pharmaceuticals | 田边三菱制药株式会社 | 2022-06-28 | — | — | CN | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
| CN-107922347-A | New imide derivative and its purposes as medicine | 田边三菱制药株式会社 | 2018-04-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | CHRM4 4746/4885TLR9 113/4885TLR8 1204/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | CHRM4 4653/4885TLR9 104/4885TLR8 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.